Overview and Mechanism of Action of Crizotinib

Overview and Mechanism of Action of Crizotinib

Crizotinib is a prescription medicine used to treat cancer, with its active ingredient being crizotinib. The drug works by inhibiting or blocking signaling pathways related to cancer cell growth, thereby controlling tumor progression. It can slow or even stop the progression of lung cancer and may lead to tumor shrinkage. The marketed formulation in Denmark is a hard capsule of 200mg and 250mg, and it should be used under the supervision of a physician experienced in cancer treatment. The package insert specifically notes that “you” refers to both adult patients and caregivers of children or adolescents.

Indication of Crizotinib: Non-Small Cell Lung Cancer

XALKORI is primarily used to treat a specific type of lung cancer – non-small cell lung cancer – in patients whose tumors have alterations or defects in the anaplastic lymphoma kinase gene or ROS1 gene. If lung cancer has reached an advanced stage, crizotinib can be used as an initial treatment; if the disease is advanced and previous treatments have failed, the drug can also be selected. Current research data are mainly derived from patients with ALK-positive or ROS1-positive non-small cell lung adenocarcinoma, and information on other cell types is relatively limited.

Indication of Crizotinib in Children and Adolescents: ALCL and IMT

In addition to adult lung cancer, crizotinib is also indicated for children and adolescents aged 1 year to less than 18 years for the treatment of two specific types of tumors: anaplastic large cell lymphoma and inflammatory myofibroblastic tumor, provided the tumors have ALK gene rearrangements or defects. For ALCL, it can be used when previous treatments have failed to stop disease progression; for IMT, it can be used when surgery cannot control the disease. The dosage for pediatric patients is calculated based on body surface area, and the medication process requires adult supervision.